Agentix (AGTX) Return on Sales (2015 - 2023)

Agentix's (AGTX) quarterly Return on Sales came in at 11.08% in Q1 2023, up 53.59% on a QoQ basis from 23.87% in Q4 2022.

Agentix (AGTX) Return on Sales (2015 - 2023) Analysis & Trends

Agentix (AGTX) has 7 years of Return on Sales data on file, last reported at 11.08% in Q1 2023.

Quarterly Return on Sales changed N/A year-over-year to 11.08% in Q1 2023, while the trailing twelve-month figure through Mar 2023 was 11.08% (changed N/A YoY) and the FY2022 annual result came in at 21.18%, changed N/A from the prior year.
Return on Sales improved to 11.08% in Q1 2023, from 23.87% in the prior quarter.
In the past five years, Return on Sales ranged from a high of 0.85% in Q2 2019 to a low of 23.87% in Q4 2022.
A 4-year average of 12.03% and a median of 11.08% in 2023 frame the typical range for Return on Sales.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	138.83 Bn	130.98 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	85.79 Bn	77.79 Bn	3.93 Bn	0.00%
3	Argenx Se	64.95 Bn	59.77 Bn	1.37 Bn	0.00%
4	Moderna	58.59 Bn	53.46 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	41.93 Bn	36.83 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.52 Bn	28.21 Bn	992.69 Mn	0.00%
7	BioNTech SE	27.98 Bn	9.58 Bn	668.28 Mn	0.00%
8	Insmed	27.42 Bn	26.26 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	0.00%
10	Agentix	801,339.00	801,301.00	-	-

Download Data